CoChat
Sign Up
Cited by 47

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Hegde, Sheila M., Claggett, Brian L., Wang, Xiaowen, Jering, Karola, Prasad, Narayana, Roshanali, Farideh, Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Abraham, Theodore P., Cardim, Nuno, Coats, Caroline J., Kramer, Christopher M., Maron, Martin S., Michels, Michelle, Olivotto, Iacopo, Saberi, Sara, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Meng, Lisa, Wohltman, Amy, Malik, Fady I., Solomon, Scott D.·2024·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2024.08.002
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2024.08.002

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

(A) Left ventricular out fl ow tract (LVOT) gradient at rest over time. (B) LVOT gradient with Valsalva over time. (C) Left ventricular ejection fraction (LVEF) over time. (D) Left atrial (LA) volume index over time. (C) LVOT gradient at rest over time. (D) LVOT gradient with Valsalva over time. (E) Lateral early diastolic mitral annular velocity (e ʹ ) over time. (F) Septal e ʹ velocity over time. (G) Lateral ratio between early mitral in fl ow velocity and early diastolic mitral annular velocity (E/e ʹ ) over time. (H) Lateral E/e ʹ over time. Vertical dashed line indicates treatment period of 24 weeks followed by a 4-week washout period. P values re fl ect placebo-corrected treatment difference at 24 weeks compared with baseline adjusted for strati fi cation by beta-blockers and cardiopulmonary exercise testing mode (bicycle vs treadmill). A and B adapted with permission from Massachusetts Medical Society from Maron et al. 14
(A) Left ventricular out fl ow tract (LVOT) gradient at rest over time. (B) LVOT gradient with Valsalva over time. (C) Left ventricular ejection fraction (LVEF) over time. (D) Left atrial (LA) volume index over time. (C) LVOT gradient at rest over time. (D) LVOT gradient with Valsalva over time. (E) Lateral early diastolic mitral annular velocity (e ʹ ) over time. (F) Septal e ʹ velocity over time. (G) Lateral ratio between early mitral in fl ow velocity and early diastolic mitral annular velocity (E/e ʹ ) over time. (H) Lateral E/e ʹ over time. Vertical dashed line indicates treatment period of 24 weeks followed by a 4-week washout period. P values re fl ect placebo-corrected treatment difference at 24 weeks compared with baseline adjusted for strati fi cation by beta-blockers and cardiopulmonary exercise testing mode (bicycle vs treadmill). A and B adapted with permission from Massachusetts Medical Society from Maron et al. 14CC-BY-NC-ND · From the PDF
(A) Prevalence of abnormal LV diastolic function measures (septal e ʹ or lateral e ʹ , average E/e ʹ , left atrial volume index [LAVI]) at baseline and 24 weeks by treatment group. (B) Change in number of patients and number of abnormal LV diastolic function measures by treatment group. Figures created with https:// fl ourish.studio/. Abbreviations as in Figure 1 .
(A) Prevalence of abnormal LV diastolic function measures (septal e ʹ or lateral e ʹ , average E/e ʹ , left atrial volume index [LAVI]) at baseline and 24 weeks by treatment group. (B) Change in number of patients and number of abnormal LV diastolic function measures by treatment group. Figures created with https:// fl ourish.studio/. Abbreviations as in Figure 1 .CC-BY-NC-ND · From the PDF
(A) Left ventricular (LV) global longitudinal strain over time. (B) LV global circumferential strain over time. Vertical dashed line indicates treatment period of 24 weeks followed by a 4-week washout period. P values re fl ect placebo-corrected treatment difference at 24 weeks compared with baseline adjusted for strati fi cation by beta-blockers and cardiopulmonary exercise testing mode (bicycle vs treadmill). Absolute strain values are presented.
(A) Left ventricular (LV) global longitudinal strain over time. (B) LV global circumferential strain over time. Vertical dashed line indicates treatment period of 24 weeks followed by a 4-week washout period. P values re fl ect placebo-corrected treatment difference at 24 weeks compared with baseline adjusted for strati fi cation by beta-blockers and cardiopulmonary exercise testing mode (bicycle vs treadmill). Absolute strain values are presented.CC-BY-NC-ND · From the PDF
The change in LV global circumferential strain (GCS) is associated with change in LVEF in a regression model additionally adjusted for baseline LV GCS, LVEF, resting LVOT gradient, Valsalva LVOT gradient, average E/e ʹ , and the randomization strati fi cation factors (beta-blocker use, cardiopulmonary exercise testing modality). Abbreviations as in Figure 1 .
The change in LV global circumferential strain (GCS) is associated with change in LVEF in a regression model additionally adjusted for baseline LV GCS, LVEF, resting LVOT gradient, Valsalva LVOT gradient, average E/e ʹ , and the randomization strati fi cation factors (beta-blocker use, cardiopulmonary exercise testing modality). Abbreviations as in Figure 1 .CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Ommen, 2024, 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 83, 2324, 10.1016/j.jacc.2024.02.014 · DOI
  2. Geske, 2018, Hypertrophic cardiomyopathy: clinical update, JACC Heart Fail, 6, 364, 10.1016/j.jchf.2018.02.010 · DOI
  3. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  4. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  5. Nagueh, 2022, J Am Soc Echocardiogr, 35, 533, 10.1016/j.echo.2022.03.012 · DOI
  6. Cardim, 2015, Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association, Eur Heart J Cardiovasc Imaging, 16, 280, 10.1093/ehjci/jeu291 · DOI
  7. Olivotto, 2020, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X · DOI · Paper page
  8. Desai, 2023, Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial, JAMA Cardiol, 8, 968, 10.1001/jamacardio.2023.3342 · DOI
  9. Hegde, 2021, Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 2518, 10.1016/j.jacc.2021.09.1381 · DOI
  10. Heydari, 2023, 3-Dimensional strain analysis of hypertrophic cardiomyopathy: insights from the NHLBI International HCM Registry, JACC Cardiovasc Imaging, 16, 478, 10.1016/j.jcmg.2022.10.005 · DOI
  11. Chuang, 2021, Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy, J Med Chem, 64, 14142, 10.1021/acs.jmedchem.1c01290 · DOI
  12. Malik, 2022, A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants, JACC Basic Transl Sci, 7, 763, 10.1016/j.jacbts.2022.04.008 · DOI
  13. Maron, 2023, Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 81, 34, 10.1016/j.jacc.2022.10.020 · DOI
  14. Maron, 2024, Aficamten for symptomatic obstructive hypertrophic cardiomyopathy, N Engl J Med, 390, 1849, 10.1056/NEJMoa2401424 · DOI · Paper page
  15. Coats, 2024, Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design, JACC Heart Fail, 12, 199, 10.1016/j.jchf.2023.10.004 · DOI
  16. Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 28, 1, 10.1016/j.echo.2014.10.003 · DOI · Paper page
  17. Shah, 2014, Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study, Circ Cardiovasc Imaging, 7, 173, 10.1161/CIRCIMAGING.113.000736 · DOI
  18. Nagueh, 2016, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 29, 277, 10.1016/j.echo.2016.01.011 · DOI · Paper page
  19. Shah, 2017, Contemporary assessment of left ventricular diastolic function in older adults: the Atherosclerosis Risk in Communities study, Circulation, 135, 426, 10.1161/CIRCULATIONAHA.116.024825 · DOI
  20. Corona-Villalobos, 2016, Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography, Int J Cardiovasc Imaging, 32, 945, 10.1007/s10554-016-0858-4 · DOI
  21. Hindieh, 2017, Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 10, 10.1161/CIRCIMAGING.117.006309 · DOI
  22. Mazur, 2001, Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy, Circulation, 103, 1492, 10.1161/01.CIR.103.11.1492 · DOI
  23. Finocchiaro, 2016, Impact of septal reduction on left atrial size and diastole in hypertrophic cardiomyopathy, Echocardiography, 33, 686, 10.1111/echo.13158 · DOI
  24. Moravsky, 2013, Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 26, 893, 10.1016/j.echo.2013.05.012 · DOI
  25. Dabrowski, 2019, Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy, Kardiol Pol, 77, 181, 10.5603/KP.a2018.0242 · DOI
  26. Ho, 2009, Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 2, 314, 10.1161/CIRCGENETICS.109.862128 · DOI
  27. Villemain, 2019, Myocardial stiffness evaluation using noninvasive shear wave imaging in healthy and hypertrophic cardiomyopathic adults, JACC Cardiovasc Imaging, 12, 1135, 10.1016/j.jcmg.2018.02.002 · DOI
  28. Weissler-Snir, 2019, Left atrial remodeling postseptal myectomy for severe obstructive hypertrophic cardiomyopathy: Analysis by two-dimensional speckle-tracking echocardiography, Echocardiography, 36, 276, 10.1111/echo.14226 · DOI
  29. Nagueh, 1999, Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy, Circulation, 99, 344, 10.1161/01.CIR.99.3.344 · DOI
  30. Collier, 2017, A test in context: myocardial strain measured by speckle-tracking echocardiography, J Am Coll Cardiol, 69, 1043, 10.1016/j.jacc.2016.12.012 · DOI
  31. Afonso, 2012, Two-dimensional strain profiles in patients with physiological and pathological hypertrophy and preserved left ventricular systolic function: a comparative analyses, BMJ Open, 2, 10.1136/bmjopen-2012-001390 · DOI
  32. Tower-Rader, 2019, Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature, JACC Cardiovasc Imaging, 12, 1930, 10.1016/j.jcmg.2018.07.016 · DOI
  33. Kobayashi, 2013, Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy, Am Heart J, 166, 10.1016/j.ahj.2013.06.011 · DOI
  34. Yingchoncharoen, 2013, Normal ranges of left ventricular strain: a meta-analysis, J Am Soc Echocardiogr, 26, 185, 10.1016/j.echo.2012.10.008 · DOI
  35. Cui, 2023, Preoperative left ventricular longitudinal strain predicts outcome of septal myectomy for obstructive hypertrophic cardiomyopathy, J Thorac Cardiovasc Surg, 166, 492, 10.1016/j.jtcvs.2021.09.058 · DOI
  36. Calin, 2020, Role of advanced left ventricular imaging in adults with aortic stenosis, Heart, 106, 962, 10.1136/heartjnl-2019-315211 · DOI
  37. Carasso, 2011, Relation of myocardial mechanics in severe aortic stenosis to left ventricular ejection fraction and response to aortic valve replacement, Am J Cardiol, 107, 1052, 10.1016/j.amjcard.2010.11.032 · DOI
  38. Dahl, 2019, Assessment of subclinical left ventricular dysfunction in aortic stenosis, JACC Cardiovasc Imaging, 12, 163, 10.1016/j.jcmg.2018.08.040 · DOI
  39. Streeter, 1969, Fiber orientation in the canine left ventricle during diastole and systole, Circ Res, 24, 339, 10.1161/01.RES.24.3.339 · DOI
  40. Sengupta, 2006, Left ventricular structure and function: basic science for cardiac imaging, J Am Coll Cardiol, 48, 1988, 10.1016/j.jacc.2006.08.030 · DOI
  41. Wessly, 2023, Early observations on effects of mavacamten on left atrial function in obstructive hypertrophic cardiomyopathy patients, JACC Cardiovasc Imaging, 16, 1633, 10.1016/j.jcmg.2023.06.008 · DOI
  42. Sulaiman, 2021, The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients, Egypt Heart J, 73, 20, 10.1186/s43044-021-00142-z · DOI
  43. Dong, 2022, Early predictive value of NT-proBNP combined with echocardiography in anthracyclines induced cardiotoxicity, Front Surg, 9, 10.3389/fsurg.2022.898172 · DOI
  44. Erez, 2024, Exercise limitation in hypertrophic cardiomyopathy: combined stress echocardiography and cardiopulmonary exercise test, ESC Heart Fail, 11, 2287, 10.1002/ehf2.14776 · DOI
  45. Saijo, 2022, Impact of left atrial strain mechanics on exercise intolerance and need for septal reduction therapy in hypertrophic cardiomyopathy, Eur Heart J Cardiovasc Imaging, 23, 238, 10.1093/ehjci/jeab001 · DOI
  46. Zegkos, 2023, Left atrial myopathy is associated with exercise incapacity and ventilatory inefficiency in hypertrophic cardiomyopathy, Heart Lung Circ, 32, 215, 10.1016/j.hlc.2022.10.002 · DOI
  47. Sachdev, 2005, Left atrial volumetric remodeling is predictive of functional capacity in nonobstructive hypertrophic cardiomyopathy, Am Heart J, 149, 730, 10.1016/j.ahj.2004.07.017 · DOI
  48. Yang, 2009, Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 22, 1338, 10.1016/j.echo.2009.09.016 · DOI
  49. Zhu, 2023, Medical therapies to improve left ventricular outflow obstruction and diastolic function in hypertrophic cardiomyopathy, JACC Adv, 2, 10.1016/j.jacadv.2023.100622 · DOI
  50. Dybro, 2021, Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 2505, 10.1016/j.jacc.2021.07.065 · DOI
  51. Dybro, 2023, Metoprolol improves left ventricular longitudinal strain at rest and during exercise in obstructive hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 36, 196, 10.1016/j.echo.2022.09.008 · DOI

Cited by

Sorted by citations

Metadata

Authors
Hegde, S. M., Claggett, B. L., Wang, X., Jering, K., Prasad, N., Roshanali, F., Masri, A., Nassif, M. E., Barriales-Villa, R., Abraham, T. P., Cardim, N., Coats, C. J., Kramer, C. M., Maron, M. S., Michels, M., Olivotto, I., Saberi, S., Jacoby, D. L., Heitner, S. B., Kupfer, S., Meng, L., Wohltman, A., Malik, F. I., & Solomon, S. D.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2024-11
Volume
84
Issue
19
Pages
1789-1802
ISSN
0735-1097
DOI
10.1016/j.jacc.2024.08.002
Cited by
47
References
2
Language
en
Licence
Funders
Cytokinetics Inc

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review